Levers For Streamlining And Optimizing The Biosimilar Process

Why It Matters

By aligning upstream and downstream controls with precise analytics, firms can accelerate biosimilar approval and lower manufacturing costs, strengthening their position against originator biologics.

Key Takeaways

• Biosimilar developers must balance yield with strict quality attributes.
• Advanced CHO cell lines now achieve 5‑10 g/L productivity.
• Media, feed, pH, and oxygen are critical process levers.
• Mid‑range reference targets reduce risk of out‑of‑spec batches.
• Integrated analytics guide upstream and downstream optimization decisions.

Summary

The panel discussed how biosimilar developers can streamline production by leveraging modern cell‑line engineering and a systematic set of process levers. Unlike de‑novo biologics, biosimilars must replicate a defined quality attribute envelope while seeking cost efficiencies.

Advances in CHO cell line development now deliver 5‑10 g/L titers, a dramatic jump from two decades ago. Developers use a two‑pronged strategy: an upstream culture that maximizes productivity without compromising critical quality attributes, and a downstream platform—protein A, ion exchange, and hydrophobic interaction chromatography—tuned to preserve those attributes. Levers such as media composition, feed strategy, pH, temperature, and dissolved‑oxygen control are explored through multivariate studies because they interact.

Regulatory guidance emphasizes hitting the mid‑range of the reference product’s attribute distribution. As one speaker noted, “If you teeter on the high or low end, you risk producing lots that fall outside the acceptable range.” Analytical assays therefore become the cornerstone for defining those target windows early in development.

Embedding analytics and process‑leverage optimization from the outset reduces batch‑to‑batch variability, shortens development timelines, and improves cost‑of‑goods, giving biosimilar manufacturers a competitive edge in a crowded market.

Original Description

New and more advanced production methods mean biosimilar developers can produce their own versions of commercial drugs with greater efficiency. Levers like cell line engineering and bioreactor controls make it easier to increase productivity. Biologics Consulting Group Principal Consultant Vince Narbut walked through some of the unit operations ripe for optimizing during Bioprocess Online Live: Process Control's Increasing Role In Biosimilar Approval.

When changing key processes, it is important to aim for the mid-range of reference product attribute data to ensure consistent similarity, since developers are now less likely to have clinical efficacy study data to fall back on.